Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

APOL1 toxin, innate immunity, and kidney injury.

Limou S, Dummer PD, Nelson GW, Kopp JB, Winkler CA.

Kidney Int. 2015 Jul;88(1):28-34. doi: 10.1038/ki.2015.109. Epub 2015 Apr 8. Review.

2.

Apolipoprotein L1 Variant Associated with Increased Susceptibility to Trypanosome Infection.

Cuypers B, Lecordier L, Meehan CJ, Van den Broeck F, Imamura H, Büscher P, Dujardin JC, Laukens K, Schnaufer A, Dewar C, Lewis M, Balmer O, Azurago T, Kyei-Faried S, Ohene SA, Duah B, Homiah P, Mensah EK, Anleah F, Franco JR, Pays E, Deborggraeve S.

MBio. 2016 Apr 12;7(2):e02198-15. doi: 10.1128/mBio.02198-15.

3.

[Molecular dialogue between African trypanosomes and humans].

Pays E.

Bull Mem Acad R Med Belg. 2011;166(10-12):358-63; discussion 364-5. French.

PMID:
23082501
4.

Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.

Hu CA, Klopfer EI, Ray PE.

FEBS Lett. 2012 Apr 5;586(7):947-55. doi: 10.1016/j.febslet.2012.03.002. Epub 2012 Mar 8. Review.

5.

Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.

Khatua AK, Cheatham AM, Kruzel ED, Singhal PC, Skorecki K, Popik W.

Am J Physiol Cell Physiol. 2015 Jul 1;309(1):C22-37. doi: 10.1152/ajpcell.00384.2014. Epub 2015 Apr 29.

6.

APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.

Kruzel-Davila E, Shemer R, Ofir A, Bavli-Kertselli I, Darlyuk-Saadon I, Oren-Giladi P, Wasser WG, Magen D, Zaknoun E, Schuldiner M, Salzberg A, Kornitzer D, Marelja Z, Simons M, Skorecki K.

J Am Soc Nephrol. 2017 Apr;28(4):1117-1130. doi: 10.1681/ASN.2016050546. Epub 2016 Nov 18.

7.

APOL1 nephropathy: from gene to mechanisms of kidney injury.

Kruzel-Davila E, Wasser WG, Aviram S, Skorecki K.

Nephrol Dial Transplant. 2016 Mar;31(3):349-58. doi: 10.1093/ndt/gfu391. Epub 2015 Jan 5. Review.

PMID:
25561578
8.

Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K.

Nat Med. 2017 Apr;23(4):429-438. doi: 10.1038/nm.4287. Epub 2017 Feb 20.

9.

Apolipoprotein L1 and Kidney Disease in African Americans.

Friedman DJ, Pollak MR.

Trends Endocrinol Metab. 2016 Apr;27(4):204-215. doi: 10.1016/j.tem.2016.02.002. Epub 2016 Mar 3. Review.

10.

APOL1 kidney risk alleles: population genetics and disease associations.

Limou S, Nelson GW, Kopp JB, Winkler CA.

Adv Chronic Kidney Dis. 2014 Sep;21(5):426-33. doi: 10.1053/j.ackd.2014.06.005. Review.

11.

Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR.

Science. 2010 Aug 13;329(5993):841-5. doi: 10.1126/science.1193032. Epub 2010 Jul 15.

12.

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J.

Nat Med. 2017 Aug;23(8):945-953. doi: 10.1038/nm.4362. Epub 2017 Jun 26.

13.

APOL1 Kidney Disease Risk Variants: An Evolving Landscape.

Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, Kopp JB.

Semin Nephrol. 2015 May;35(3):222-36. doi: 10.1016/j.semnephrol.2015.04.008. Review.

14.

Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells.

Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, Freedman BI, Parks JS, Shelness GS.

J Lipid Res. 2015 Aug;56(8):1583-93. doi: 10.1194/jlr.M059733. Epub 2015 Jun 18.

15.

Evolution of the primate trypanolytic factor APOL1.

Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ, Raper J.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2130-9. doi: 10.1073/pnas.1400699111. Epub 2014 May 7.

16.

APOL1 localization in normal kidney and nondiabetic kidney disease.

Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR.

J Am Soc Nephrol. 2011 Nov;22(11):2119-28. doi: 10.1681/ASN.2011010069. Epub 2011 Oct 13.

17.

The evolving science of apolipoprotein-L1 and kidney disease.

Chen TK, Estrella MM, Parekh RS.

Curr Opin Nephrol Hypertens. 2016 May;25(3):217-25. doi: 10.1097/MNH.0000000000000222. Review.

PMID:
27023839
18.

Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.

Mikulak J, Oriolo F, Portale F, Tentorio P, Lan X, Saleem MA, Skorecki K, Singhal PC, Mavilio D.

Retrovirology. 2016 Sep 6;13(1):63. doi: 10.1186/s12977-016-0296-3.

19.

Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.

Nadkarni GN, Galarneau G, Ellis SB, Nadukuru R, Zhang J, Scott SA, Schurmann C, Li R, Rasmussen-Torvik LJ, Kho AN, Hayes MG, Pacheco JA, Manolio TA, Chisholm RL, Roden DM, Denny JC, Kenny EE, Bottinger EP.

J Am Coll Cardiol. 2017 Mar 28;69(12):1564-1574. doi: 10.1016/j.jacc.2017.01.040.

20.

BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins.

Heneghan JF, Vandorpe DH, Shmukler BE, Giovinazzo JA, Raper J, Friedman DJ, Pollak MR, Alper SL.

Am J Physiol Cell Physiol. 2015 Sep 1;309(5):C332-47. doi: 10.1152/ajpcell.00142.2015. Epub 2015 Jun 24. Erratum in: Am J Physiol Cell Physiol. 2015 Dec 15;309(12):C856. Giovinnazo, J A [corrected to Giovinazzo, J A].

Supplemental Content

Support Center